Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Sensitization of (colon) cancer cells to death receptor related therapies: a report from the FP6-ONCODEATH research consortium.

Pintzas A, Zhivotovsky B, Workman P, Clarke PA, Linardopoulos S, Martinou JC, Lacal JC, Robine S, Nasioulas G, Andera L.

Cancer Biol Ther. 2012 May;13(7):458-66. doi: 10.4161/cbt.19600. Epub 2012 May 1. Review.

PMID:
22406997
2.

The TRAIL apoptotic pathway in cancer onset, progression and therapy.

Johnstone RW, Frew AJ, Smyth MJ.

Nat Rev Cancer. 2008 Oct;8(10):782-98. doi: 10.1038/nrc2465. Review.

PMID:
18813321
3.

Therapeutic targeting of CD95 and the TRAIL death receptors.

Gerspach J, Pfizenmaier K, Wajant H.

Recent Pat Anticancer Drug Discov. 2011 Sep;6(3):294-310. doi: 10.2174/157489211796957739. Review.

PMID:
21762072
4.

Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models.

Liu Y, Hawkins OE, Vilgelm AE, Pawlikowski JS, Ecsedy JA, Sosman JA, Kelley MC, Richmond A.

Clin Cancer Res. 2015 Dec 1;21(23):5338-48. doi: 10.1158/1078-0432.CCR-15-0293. Epub 2015 Jul 7.

5.

Low-dose combinations of LBH589 and TRAIL can overcome TRAIL-resistance in colon cancer cell lines.

Lee SC, Cheong HJ, Kim SJ, Yoon J, Kim HJ, Kim KH, Kim SH, Kim HJ, Bae SB, Kim CK, Lee N, Lee KT, Park SK, Hong DS, Park HS, Won JH.

Anticancer Res. 2011 Oct;31(10):3385-94.

PMID:
21965751
6.

The antidiabetic drug ciglitazone induces high grade bladder cancer cells apoptosis through the up-regulation of TRAIL.

Plissonnier ML, Fauconnet S, Bittard H, Lascombe I.

PLoS One. 2011;6(12):e28354. doi: 10.1371/journal.pone.0028354. Epub 2011 Dec 12.

7.

2-methoxy-5-amino-N-hydroxybenzamide sensitizes colon cancer cells to TRAIL-induced apoptosis by regulating death receptor 5 and survivin expression.

Stolfi C, Caruso R, Franzè E, Rizzo A, Rotondi A, Monteleone I, Fantini MC, Pallone F, Monteleone G.

Mol Cancer Ther. 2011 Oct;10(10):1969-81. doi: 10.1158/1535-7163.MCT-11-0316. Epub 2011 Aug 4.

9.

Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy.

Wang S, El-Deiry WS.

Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15095-100. Epub 2003 Nov 26.

10.

Methyl jasmonate down-regulates survivin expression and sensitizes colon carcinoma cells towards TRAIL-induced cytotoxicity.

Raviv Z, Zilberberg A, Cohen S, Reischer-Pelech D, Horrix C, Berger MR, Rosin-Arbesfeld R, Flescher E.

Br J Pharmacol. 2011 Nov;164(5):1433-44. doi: 10.1111/j.1476-5381.2011.01419.x.

11.

Bax is essential for death receptor-mediated apoptosis in human colon cancer cells.

Zhu S, Li T, Tan J, Yan X, Zhang D, Zheng C, Chen Y, Xiang Z, Cui H.

Cancer Biother Radiopharm. 2012 Nov;27(9):577-81. doi: 10.1089/cbr.2012.1256.

PMID:
23113596
12.

LY294002 potentiates the anti-cancer effect of oxaliplatin for gastric cancer via death receptor pathway.

Liu J, Fu XQ, Zhou W, Yu HG, Yu JP, Luo HS.

World J Gastroenterol. 2011 Jan 14;17(2):181-90. doi: 10.3748/wjg.v17.i2.181.

13.

Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.

Tortora G, Bianco R, Daniele G, Ciardiello F, McCubrey JA, Ricciardi MR, Ciuffreda L, Cognetti F, Tafuri A, Milella M.

Drug Resist Updat. 2007 Jun;10(3):81-100. Epub 2007 May 7. Review.

14.

STI571 reduces TRAIL-induced apoptosis in colon cancer cells: c-Abl activation by the death receptor leads to stress kinase-dependent cell death.

Huang DY, Chao Y, Tai MH, Yu YH, Lin WW.

J Biomed Sci. 2012 Mar 30;19:35. doi: 10.1186/1423-0127-19-35.

15.

Bakuchiol sensitizes cancer cells to TRAIL through ROS- and JNK-mediated upregulation of death receptors and downregulation of survival proteins.

Park MH, Kim JH, Chung YH, Lee SH.

Biochem Biophys Res Commun. 2016 Apr 29;473(2):586-92. doi: 10.1016/j.bbrc.2016.03.127. Epub 2016 Mar 28.

PMID:
27033605
16.

Sensitization of tumor cells by targeting histone deacetylases.

Perego P, Zuco V, Gatti L, Zunino F.

Biochem Pharmacol. 2012 Apr 15;83(8):987-94. doi: 10.1016/j.bcp.2011.11.010. Epub 2011 Nov 22. Review.

PMID:
22120677
17.

Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells.

Lippa MS, Strockbine LD, Le TT, Branstetter DG, Strathdee CA, Holland PM.

Apoptosis. 2007 Aug;12(8):1465-78.

PMID:
17440816
18.

The TRAIL of oncogenes to apoptosis.

Oikonomou E, Pintzas A.

Biofactors. 2013 Jul-Aug;39(4):343-54. doi: 10.1002/biof.1112. Epub 2013 Jun 29. Review.

PMID:
23813857
19.

(E)-4-(3-(3,5-dimethoxyphenyl)allyl)-2-methoxyphenol inhibits growth of colon tumors in mice.

Zheng J, Park MH, Son DJ, Choi MG, Choi JS, Nam KT, Kim HD, Rodriguez K, Gann B, Ham YW, Han SB, Hong JT.

Oncotarget. 2015 Dec 8;6(39):41929-43. doi: 10.18632/oncotarget.5861.

20.

Ilimaquinone induces death receptor expression and sensitizes human colon cancer cells to TRAIL-induced apoptosis through activation of ROS-ERK/p38 MAPK-CHOP signaling pathways.

Do MT, Na M, Kim HG, Khanal T, Choi JH, Jin SW, Oh SH, Hwang IH, Chung YC, Kim HS, Jeong TC, Jeong HG.

Food Chem Toxicol. 2014 Sep;71:51-9. doi: 10.1016/j.fct.2014.06.001. Epub 2014 Jun 12.

PMID:
24930757

Supplemental Content

Support Center